99Z.F MODUS THERAPEUTICS HLDG
- Market cap
- EUR 541K
- P/E
- -
- P/B
- 0.58x
- ROE
- -154.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 99Z.F undervalued?
Graham numberThe Graham number of MODUS THERAPEUTICS HLDG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MODUS THERAPEUTICS HLDG fundamental analysis
No fundamental analysis for MODUS THERAPEUTICS HLDG yet.
MODUS THERAPEUTICS HLDG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MODUS THERAPEUTICS HLDG
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Full company profileMODUS THERAPEUTICS HLDG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MODUS THERAPEUTICS HLDG annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -20.7M | -18.0M | -16.4M | -15.8M | -18.1M | -15.9M |
| EBITDA | - | -18.0M | -16.4M | -15.5M | -18.1M | -15.9M |
| Net Income | -20.7M | -18.3M | -17.9M | -15.5M | -18.5M | -15.9M |
| EPS | -0.51 | -0.45 | -0.20 | -0.17 | -0.15 | -0.11 |
| Balance Sheet | ||||||
| Total Assets | 21.2M | 11.3M | 20.0M | 4.88M | 12.7M | 13.3M |
| Total Liabilities | 5.46M | 13.9M | 2.36M | 2.75M | 3.62M | 3.04M |
| Shareholders' Equity | 15.7M | -2.59M | 17.7M | 2.14M | 9.07M | 10.2M |
| Cash & Short-term Investments | 20.6M | 10.4M | 19.1M | 4.38M | 11.4M | 12.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -16.1M | -21.7M | -16.7M | -14.7M | -18.1M | -16.0M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -16.1M | -21.7M | -16.7M | -14.7M | -18.1M | -16.0M |
| Ratios | ||||||
| ROE | -131.5% | - | -101.2% | -727.4% | -204.4% | -154.8% |
| ROA | -97.6% | -162.5% | -89.3% | -318.3% | -146.2% | -119.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
MODUS THERAPEUTICS HLDG dividends
MODUS THERAPEUTICS HLDG has not paid dividends in the last 6 fiscal years.
Who owns MODUS THERAPEUTICS HLDG
- Insiders 67.93%
- Institutions 2.56%
- Public & others 29.51%
- Shares outstanding 169M
- Free float 33.4M
MODUS THERAPEUTICS HLDG company profile
- Company name
- MODUS THERAPEUTICS HLDG
- Ticker
- 99Z.F
- ISIN
- SE0015987904
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- Olof Palmes gata 29 IV, Stockholm, Sweden, 111 22
- Phone
- 46 8 50 13 70 00
- Website
- modustx.com
About MODUS THERAPEUTICS HLDG
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
MODUS THERAPEUTICS HLDG management
2- Dr. John Öhd M.D., Ph.D.Chief Executive Officer · born 1971
- Mr. Claes LindbladCFO & Head of IR · born 1967